Valeritas Holdings Inc (NASDAQ:VLRX) Shorts Rose By 968.21%

June 27, 2018 - By Clara Lewis

It was noted an increase on Valeritas Holdings Inc (NASDAQ:VLRX)’s short interest with 968.21%. It was published in June by FINRA the 161,300 short interest on VLRX. Previously was reported up change of 968.21% from 15,100 shares. Former VLRX’s position will need 0 days to recover. It has 2.20 million average volume. Valeritas Holdings Inc float short is 6.82%.

The stock decreased 4.00% or $0.06 during the last trading session, hitting $1.44.Valeritas Holdings, Inc. has volume of 561,423 shares. Since June 27, 2017 VLRX has declined 68.29% and is downtrending. VLRX underperformed by 80.86% the S&P500.

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on developing technologies to treat patients with Type 2 diabetes.The company has $35.58 million market cap. It offers V-Go, a disposable insulin delivery device for basal-bolus therapy.Last it reported negative earnings. The firm also develops h-Patch, a controlled delivery technology platform; Mini-Ject, a disposable needle-free injection system that delivers drugs ranging from small molecules to large proteins, as well as antibodies and vaccines; and Micro-Trans microneedle array patch technology to deliver drugs into the dermis layer of the skin.

For more Valeritas Holdings, Inc. (NASDAQ:VLRX) news posted briefly go to: Streetinsider.com, Nasdaq.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “Pre-Open Movers 06/25: (XRM) (VLRX) (GTN) Higher; (SPHS) (MACK) (ATI) Lower (more…)” posted on June 25, 2018, “Valeritas ENABLE Study Demonstrates Significant Clinical Benefits of V-Go in Patients with Type 2 Diabetes Who …” on June 25, 2018, “25 Stocks Moving In Monday’s Pre-Market Session” with a publish date: June 25, 2018, “36 Stocks Moving In Monday’s Mid-Day Session” and the last “44 Biggest Movers From Yesterday” with publication date: June 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.